-
1
Establishing the cost of implementing a performance-based, managed entry agreement for a hypothetical CAR T-cell therapy
Published 2018-01-01“…Journal of Market Access & Health Policy…”
Get full text
Article -
2
Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries
Published 2020-01-01“…Journal of Market Access & Health Policy…”
Get full text
Article -
3
Data collection infrastructure for patient outcomes in the UK – opportunities and challenges for cell and gene therapies launching
Published 2019-01-01“…Journal of Market Access & Health Policy…”
Get full text
Article -
4
Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test
Published 2017-01-01“…Journal of Market Access & Health Policy…”
Get full text
Article -
5
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’...
Published 2018-01-01“…Journal of Market Access & Health Policy…”
Get full text
Article -
6
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
Published 2019-01-01“…Journal of Market Access & Health Policy…”
Get full text
Article